Immunocidin® Demonstrates Acceptable Safety Profile with IV Use in Dogs and Cats

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

NovaVive Supports World Antibiotic Awareness Week

It's World Antibiotic Awareness Week and NovaVive is doing its part to help address the concern about antibiotic resistance by offering antibiotic alternatives for animals to the veterinary community and livestock/pet owners.

learn more

Amplimune® Receives Canadian OMRI Listing for Use in Organic Cattle Production

The Company's regulator-approved immunotherapy for calf scours, Amplimune®, has received an Organic Materials Review Institute (OMRI) Listing in Canada. This means that Amplimune may be used in organic cattle production.

learn more

Mycobacterium Cell Wall Fraction (MCWF) Demonstrates Beneficial Efficacy in Dairy Cattle

NovaVive made two presentations at the World Buiatrics Congress in Sapporo, Japan today. Both presentations highlighted efficacy of MCWF in mature dairy cattle. More research is required, but these results are very promising.

learn more

Follow NovaVive on Social Media.